-
-
Finance -
Finance -
Editor's Choice -
Finance
Editor’s Choice
Editor's Choice
Fecal Microbiota Transplantation (FMT): Global Industry and Regulatory Overview
First described in the 4th Century in China, practiced since the 1950’s and re-discovered relatively recently [1][2], Fecal Microbiota Transplantation (FMT) or simply Fecal Transplant is a therapeutic approach in which more or less processed […]
Editor's Choice
Validation of the predictive role of A.muciniphila for response and resistance to PD1 blockade in non small cell lung cancers
Editor's Choice
Did you miss Probiota Copenhagen 2022? Catch up now!
With 400 registered and 60 people on the waiting list, this edition of Probiota, the first in-person since 2020, broke all records. The event started with the best and only way it is meant to: […]
In Case you Missed it:
Pharma & Human Health
Bacthera: Enabling the Live Biotherapeutic Industry
Bacthera tailor live biotherapeutic product services to meet your needs, whether you are an early start-up, a fully established biotech company, or part of a pharma company working with live biotherapeutic products. We offer a […]
Pharma & Human Health
Unprecedented case series advances promise of phage therapy
An international team of researchers, led by scientists at University of California San Diego School of Medicine and the University of Pittsburgh, report promising results from the largest case series yet of patients treated with […]
Pharma & Human Health
Seres Therapeutics Announces Confirmatory Results From Ser-109 Ecospor Iv Open-Label Study In Recurrent C. Difficile Infection
Seres Therapeutics, Inc. (Nasdaq: MCRB) announced confirmatory results from ECOSPOR IV, an open-label study for SER-109, an investigational oral microbiome therapeutic for the prevention of recurrent C. difficile infection (rCDI). The overall safety profile observed […]
Pharma & Human Health
Pherecydes Pharma Obtains AAC Early Access Program Approval From the ANSM for its anti-Staphylococcus aureus Phages
Pherecydes Pharma (Paris:ALPHE) (FR0011651694 – ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces that it has been granted AAC Early Access Program approval by the […]
Pharma & Human Health
Ethical challenges in microbiome research
A human rights activist and a group of anthropologists and human biologists are casting a critical lens on the way that microbiome research is conducted with Indigenous peoples. While this isn’t the first time that […]
Pharma & Human Health
Phage therapy: A model to predict its efficacy against pathogenic bacteria
Antibiotic resistance represents a major public health challenge, associated with a high mortality rate. While bacteriophages – viruses that kill bacteria – could be a solution for fighting antibiotic-resistant pathogens, various obstacles stand in the […]
Pharma & Human Health
Researchers use virus to fight bacterial infection clearing way for life-saving lung transplant
For the first time, researchers have successfully used bacteriophages – viruses that kill bacteria – to treat an antibiotic-resistant mycobacterial lung infection, clearing the way for a young National Jewish Health patient with cystic fibrosis […]
Pharma & Human Health
A refined microbiome “fingerprint” method tracks sub-strain variants of a single gut microbe strain
Casey D. Morrow, Ph.D., and colleagues at the University of Alabama at Birmingham previously developed a microbiome “fingerprint” method called WSS that identifies single strains of particular gut bacteria, through analysis of metagenomics data from […]
